What You Should Know:
- Senseonics Holdings, a medical technology company specializing in implantable continuous glucose monitoring (CGM) systems, has announced a Memorandum of Understanding (MOU) with Ascensia Diabetes Care to transition all global commercialization and distribution of its Eversense 365 and future products to Senseonics. Since 2020, Ascensia, a member of PHC Group, has held the exclusive worldwide distribution rights for Eversense products.
This strategic move is
Read More
Continuous Glucose Monitoring (CGM)
FriskaAi Integrates with Dexcom’s CGM Data for AI-Powered Diabetes Management
What You Should Know:
- FriskaAi, an AI-powered healthcare platform, has announced an agreement with Dexcom, Inc., a global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into its platform.
- The collaboration will enable FriskaAi to use continuous glucose data to support physicians and patients with actionable, personalized care management programs.
Physician-Directed Platform for Chronic Disease
Read More
Trinity Biotech Unveils CGM+: AI-Native Wearable Biosensor for Holistic Health Monitoring
What You Should Know:
- Trinity Biotech, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market.
- Now in the later stages of device development, CGM+ is Trinity’s new AI-native continuous glucose monitoring (CGM) system, combining multi-sensor data and real-time analytics to meet the
Read More
Sequel twiist AID System to Integrate with Senseonics Eversense 365 One-Year CGM
What You Should Know:
- Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement.
- The collaboration will integrate Sequel's twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, with Senseonics' Eversense® 365 CGM system.
This partnership marks a notable advancement in diabetes
Read More
FDA Clears Dexcom G7 15 Day Continuous Glucose Monitoring System
What You Should Know:
- Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.
- The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and
Read More
DME Providers Lead to Better CGM Adherence and Lower Healthcare Costs Compared to Pharmacies
What You Should Know:
- New research published in Clinical Diabetes, a peer-reviewed journal of the American Diabetes Association, reveals that patients receiving continuous glucose monitors (CGM) through durable medical equipment (DME) providers demonstrate significantly higher adherence and lower healthcare costs compared to those using pharmacy channels.
- The study, titled "Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Healthcare Costs: A
Read More
Glooko Integrates Abbott FreeStyle Libre CGM, Enhancing Diabetes Management
What You Should Know:
- Glooko, a provider of integrated digital health solutions for diabetes management, has announced a significant expansion of its platform's capabilities with the integration of Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) systems in the United States.
- The newly implemented integration allows individuals with diabetes to seamlessly synchronize data from their FreeStyle Libre CGM systems with other vital health metrics, including insulin
Read More
Sequel Med Tech’s twiist AID System to Integrate Abbott’s FreeStyle Libre 3 Plus
What You Should Know:
- Sequel Med Tech, LLC, a company focused on developing cutting-edge insulin delivery technologies, has announced that its innovative twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, will be the first to integrate Abbott’s FreeStyle Libre 3 Plus sensor, a continuous glucose monitoring (CGM) device.
- The integration marks a pivotal moment for individuals with type 1 diabetes (T1D). The twiist AID System, expected to launch in Q2 2025, is
Read More
Senseonics and Ascensia Diabetes Care Integrate Eversense® 365 CGM with SweetSpot™ Platform
What You Should Know:
- Senseonics Holdings and Ascensia Diabetes Care today announced the integration of the Eversense® 365 Continuous Glucose Monitoring (CGM) System with the SweetSpot™ diabetes management platform in the U.S.
- The collaboration aims to improve patient care and streamline diabetes management for endocrinology practices and their patients.
Enhance Diabetes Management and Improve Patient Outcomes
The integration allows SweetSpot to seamlessly access and
Read More
Dexcom Introduces Generative AI Platform for Glucose Biosensing
What You Should Know:
- Dexcom, the global leader in continuous glucose monitoring (CGM), has achieved another groundbreaking milestone by launching the first generative AI (GenAI) platform in glucose biosensing technology, Stelo.
- The Stelo platform analyzes individual health data patterns to provide personalized insights and recommendations for improving metabolic health.
AI-Powered Personalized Guidance
The Dexcom GenAI platform leverages Google Cloud's Vertex AI and
Read More
